Concepta PLC Result of AGM (4033R)
14 June 2018 - 7:22PM
UK Regulatory
TIDMCPT
RNS Number : 4033R
Concepta PLC
14 June 2018
14 June 2018
Concepta plc
("Concepta" or the "Company")
Result of AGM
Concepta plc (AIM:CPT), the UK healthcare company and developer
of a proprietary product targeted at the mobile health market and
with a primary focus on women's fertility, is pleased to announce
that at its Annual General Meeting ("AGM") held earlier today,
Thursday 14 June 2018, all resolutions were duly passed.
-ENDS-
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
NOVUM Securities Limited (Broker)
Colin Rowbury
Tel: +44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
Notes to Editors
Concepta Plc
Concepta plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus, targeted at the
personalised mobile health market with a primary focus on
unexplained infertility in women.
myLotus is currently the only consumer product which allows both
quantitative and qualitative measurements of a woman's personal LH
and human chorionic gonadotropin (hCG) hormone levels in a home
test, facilitating higher conception rates and early diagnosis of
issues with fertility hormones. The proposition of myLotus is to
help women conceive naturally.
Concepta has made significant progress recently, establishing
relationships with a number of distributors in China where myLotus
has been given cFDA approval. Concepta is initially targeting the
traditional route to market in China through Chinese hospitals and
plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and
commencing its direct-to-consumer launch in the UK and Europe in H2
2018. The Company has identified a significant global market
opportunity, with revenue potential of the Chinese and EU
unexplained infertility market estimated to be worth c.GBP600m per
annum.
Unexplained infertility refers to women that have been unable to
conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGKZLBFVQFLBBB
(END) Dow Jones Newswires
June 14, 2018 05:22 ET (09:22 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2023 to Apr 2024